SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Vivos Therapeutics reports progress on cost reductions and revenue initiatives

Vivos Therapeutics (VVOS) says it has made progress on material cost reductions and on revenue growth initiatives.

VVOS

Related stories